Table 2.
Ongoing trials of CAR T cell therapies.
| NCT number | Phase | Target (co-stimulator) | Planned enrolment | Patient population | Sponsor | Region/country | Preconditioning | Primary outcome | Status |
|---|---|---|---|---|---|---|---|---|---|
| GCP3 based | |||||||||
| 3884751 | I | GPC3 | 15 | Advanced HCC | CARsgen Therapeutics Co., Ltd. | China | Safety and tolerability | Completed | |
| 3980288 | I | GPC3 | 36 | Advanced HCC | Zhejiang Universit | China | Flu + Cyclo | Safety and tolerability | Completed |
| 4121273 | I | GPC3 | 14 | Advanced HCC | Baylor College of Medicine | USA | Flu + Cyclo | DLT | Unknown |
| 2959151 | I/II | GPC3 | 20 | Advanced HCC | Shanghai GeneChem Co., Ltd | China | Adverse events | Unknown | |
| 3146234 | I | GPC3 | 20 | Advanced HCC | RenJi Hospital | China | Flu + Cyclo | Safety and tolerability | Completed |
| 5652920 | lb/ll | GPC3 | 105 | Advanced HCC | OriCell Therapeutics Co., Ltd. | China | MTD | Recruiting | |
| 2715362 | l/ll | GPC3 (4-1BB) | 30 | Advanced HCC | Shanghai GeneChem Co., Ltd | China | Cylco | Safety and tolerability | Unknown |
| 5003895 | l | GPC3 | 38 | Advanced HCC | National Cancer Institute (NCI) | USA | Flu + Cyclo | Safety and feasibility | Recruiting |
| 5783570 | l | GPC3 | 12 | Advanced HCC | Eutilex | Korea | Adverse events | Recruiting | |
| 5103631 | l | GPC3 (IL-15) | 27 | Advanced HCC | Baylor College of Medicine | USA | Flu + Cyclo | DLT | Recruiting |
| 3302403 | l | GPC3 | 48 | Advanced HCC | Kang YU | China | Flu + Cyclo | Safety and tolerability | Unknown |
| 5070156 | l | GPC3 | 3 | Advanced HCC | Tongji University | China | Adverse events | Not recruiting | |
| 6084884 | l/ll | GPC3 | 84 | Advanced HCC | AstraZeneca | Korea and USA | Flu + Cyclo | Safety and tolerability | Recruiting |
| 6198296 | l | GCP3 (IL-15 and IL-21) | 21 | Multiple inc HCC | Baylor College of Medicine | USA | Flu + Cyclo | DLT | Not recruiting |
| 5620706 | l | GPC3 | 20 | Advanced HCC | Shenzhen University General Hospital | China | Adverse events | Recruiting | |
| 5120271 | l/ll | GPC3 | 110 | Multiple inc HCC | Sotio Biotech Inc. | USA | Flu + Cyclo | Safety and tolerability | Recruiting |
| 3198546 | l | GPC3+/-TGFβ (IL-7) | 30 | Advanced HCC | Second Affiliated Hospital of Guangzhou Medical University | China | DLT | Recruiting | |
| 5155189 | l | GPC3 | 44 | Advanced HCC | Zhejiang University | China | Adverse events | Recruiting | |
| 4951141 | l | GPC3 | 10 | Advanced HCC | Beijing Immunochina Medical Science & Technology Co., Ltd. | China | Adverse events | Unknown | |
| 2395250 | l | GPC3 | 10 | Advanced HCC | RenJi Hospital | China | Adverse events | Completed | |
| 3084380 | l/ll | GPC3 | 20 | Advanced HCC | Xinqiao Hospital of Chongqing | China | Flu + Cyclo | Safety | Unknown |
| 6144385 | l | GPC3 | 20 | Advanced HCC | Shanghai Ming Ju Biotechnology Co., Ltd. | China | Flu + Cyclo | Safety | Recruiting |
| 5926726 |
GPC3 |
12 |
Advanced HCC |
RenJi Hospital |
China |
Flu + Cyclo |
DLT and adverse events |
Recruiting |
|
| Non-GCP3 targets | |||||||||
| 3672305 | l | c-Met/PD-L1 | 50 | Advanced HCC | The Second Hospital of Nanjing Medical University | China | Flu + Cyclo | Efficacy | Unknown |
| 5323201 | l/ll | B7H3 | 15 | Advanced HCC | The Affiliated Hospital of Xuzhou Medical University | China | Flu + Cyclo | Safety and response rate | Recruiting |
| 3013712 | l/ll | EPCAM | 60 | Multiple inc HCC | First Affiliated Hospital of Chengdu Medical College | China | Toxicity | Unknown | |
| 3993743 | l | CD147 | 34 | Advanced HCC | Xijing Hospital | China | Adverse events | Unknown | |
| 5028933 | l | EPCAM | 48 | Multiple inc HCC | Zhejiang University | China | Flu + Cyclo | PK and adverse events | Recruiting |
| 5131763 | l | NKG2DL (4-1BB) | 3 | Multiple inc HCC | Fudan University | China | Adverse events | Unknown | |
| 4550663 | l | NKG2DL | 10 | Multiple inc HCC | The Affiliated Nanjing Drum Tower Hospital of Nanjing University | China | MTD and adverse events | Unknown | |
| 2587689 | l | MUC1 | 20 | Multiple inc HCC | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | China | Adverse events | Unknown | |
| 3941626 | l/ll | EGFRvIII/DR5 | 50 | Multiple inc HCC | Shenzhen BinDeBio Ltd. | China | Flu + Cyclo | Adverse events | Unknown |
| 3638206 | l/ll | EGFRvIII/DR5/C-met | 73 | Multiple inc HCC | Shenzhen BinDeBio Ltd. | China | Flu + Cyclo | Adverse events | Unknown |
Cyclo, cyclophosphamide; DLT, dose limiting toxicity; Flu, fludarabine; GPC3, glypican 3; MTD, maximum tolerated dose; NR, not reported.